SUNSHINE BIOPHARMA INC
SBFMNASDAQTrading Snapshot
- Day Range
- $0.80 – $0.82
- 52-Week Range
- $0.78 – $24.30
- Volume
- $2.24B
- Avg Volume
- $2.37B
- Shares Outstanding
- 2.4M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $36M
- Last Q Revenue
- $9M
- P/E Ratio
- -0.1
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-4.27
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +61.1%
Why Investors Own SBFM
- ✓High-growth profile — revenue up +5.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SUNSHINE BIOPHARMA INC
SBFM
StockOtter · stockotter.spaceAbout SUNSHINE BIOPHARMA INC
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 bi
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and preferential lung enrichment
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liv
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma